Workflow
申万菱信行业精选基金
icon
Search documents
投资中保持理性与耐心的重要性
Market Overview - The market has recently experienced a surge in activity, with the Shanghai Composite Index surpassing 3,800 points, particularly driven by the strong performance of the technology sector, especially in semiconductor ETFs, which saw gains exceeding 15% [1] - Notable stocks like Cambricon Technologies have seen their prices double within a month, with significant price increases including a 20% limit-up on two occasions [1] Fund Manager Performance - Some fund managers have faced criticism from investors due to underperformance in the short term, despite having strong long-term track records. For instance, the fund managed by Jia Chengdong saw a net value decline of over 8% since its inception on June 3 [1] - Xu Yan's fund has remained nearly fully in cash since its launch on March 11, leading to investor dissatisfaction due to lack of growth [1] Investment Philosophy - Established fund managers possess their own investment frameworks, but they may struggle during market fluctuations. Adhering to their investment philosophies can result in short-term underperformance [2] - Xu Yan exemplifies a value investment approach, prioritizing long-term value over short-term gains, even at the risk of missing out on opportunities [2] Investor Behavior - Investors often experience a disconnect between their initial long-term investment goals and the desire for immediate returns, especially when observing peers achieving higher short-term gains [3] - Historical data suggests that funds focused on short-term performance rankings typically fail to deliver consistent returns over time. Successful funds are those that provide stable returns across complete market cycles [3] Selection Criteria for Funds - Investors should prioritize understanding the investment philosophy of fund managers, the research capabilities of the fund company, and the alignment of the product with their risk tolerance, rather than merely chasing short-term performance [3] - Patience and rationality are emphasized as key virtues in investing, with long-term investors often reaping better rewards [3]
两个多月跌超8%,基金经理被爆在“赌”?申万菱信回应
Zhong Guo Ji Jin Bao· 2025-08-12 15:12
Core Viewpoint - The performance of the Shenwan Hongyuan Fund's Shenwan Lingshin Industry Select Mixed Fund has declined over 8% since its establishment, raising concerns about the fund manager's investment strategy and prompting a response from the company [1][4]. Fund Performance - The Shenwan Lingshin Industry Select Fund, established on June 3, has a unit net value of 0.9177 yuan as of August 8, reflecting a decline of over 8% since inception [4]. - The fund raised 1.219 billion yuan, making it one of the larger mixed equity funds launched in recent months [4]. - The fund's performance is benchmarked against a composite index consisting of 65% CSI 300, 10% Hang Seng Index, and 25% China Bond Index [4]. Fund Manager Background - The fund manager, Jia Chengdong, has 17 years of experience in the securities industry and has previously managed funds with significant performance records [5]. - Jia Chengdong joined Shenwan Lingshin in December 2024 after leaving China Merchants Fund, where he managed several successful funds [5]. Company Challenges - Shenwan Lingshin has faced multiple fund liquidations this year, including the Shenwan Lingshin Carbon Neutrality Mixed Fund and others, indicating potential issues within the company's product offerings [8]. - The company has struggled to maintain competitive performance and scale compared to peers like Tianhong Fund, with a current non-monetary scale of 70.324 billion yuan, ranking 59th in the public fund industry [9]. - Despite attempts to improve performance by hiring well-known fund managers, the results have not yet met expectations [9].
主动权益类新基金建仓节奏分化 创新药板块产品成焦点
Jing Ji Guan Cha Wang· 2025-06-18 11:25
Group 1 - The innovative drug sector has experienced a strong upward trend since May, attracting significant investor attention [1][2] - Despite the rising market, there is a notable divergence in the investment pace of newly established active equity funds, with some accelerating their investments while others remain cautious [2][3] - As of June 18, seven active equity funds were established in the eight trading days since June 9, with six showing net value fluctuations [2] Group 2 - The Ping An Hong Kong Stock Connect Medical Innovation Select Fund, initially set to close on June 25, ended its fundraising early on June 9, with a final scale of 249 million yuan [2] - The Dongfang Alpha Health Industry Fund also shortened its fundraising period from six to two trading days, ultimately raising 11 million yuan [2] - The performance of newly established funds varies, with the Invesco Great Wall Medical Industry Fund achieving a return of 27.01% as of June 17, leading among newly established funds [4][5] Group 3 - The fund manager of the Invesco Great Wall Medical Industry Fund indicated that the fund was established during a low point in the medical industry, but they remain optimistic about the sector [5][6] - The fund's portfolio had an 83.11% holding position by the end of Q1, with nearly 40% in Hong Kong stocks [5] - The manager anticipates 2025 to be a year of recovery for the industry, driven by reforms in commercial health insurance and the maturation of innovative drug companies [6] Group 4 - Despite the strong performance of the innovative drug sector, there are warnings about the inherent risks in drug development, including low success rates and high capital requirements [7] - The average success rate for drug development projects is only 10%, with a lengthy development cycle of around 10 years and costs reaching 1 billion yuan [7] - The ability of Chinese pharmaceutical companies to conduct clinical trials and commercialize products internationally still requires improvement [7]